AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. GILT
  4. [6-K] Gilat Satellite Networks Ltd Current Report (Foreign Issuer)

[6-K] Gilat Satellite Networks Ltd Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K
Rhea-AI Filing Summary

Stoke Therapeutics, Inc. (Nasdaq: STOK) filed a Form 8-K on July 10, 2025 under Item 7.01 (Regulation FD). The filing states that the company issued a press release (Exhibit 99.1) announcing the presentation of data from an analysis that informed the design of the planned Phase 3 EMPEROR study and evaluated the potential effects of the proposed zorevunersen dosing regimen. No financial metrics, study results, or timelines were included in the 8-K. The information is furnished (not filed) and therefore is not incorporated by reference into other Exchange Act or Securities Act filings unless specifically stated.

Stoke Therapeutics, Inc. (Nasdaq: STOK) ha presentato un modulo 8-K il 10 luglio 2025 ai sensi della voce 7.01 (Regolamento FD). Nel documento si comunica che la societ脿 ha rilasciato un comunicato stampa (Allegato 99.1) in cui annuncia la presentazione di dati provenienti da un鈥檃nalisi che ha guidato la progettazione dello studio di Fase 3 EMPEROR previsto e ha valutato i potenziali effetti del regime di dosaggio proposto per zorevunersen. Nel modulo 8-K non sono stati inclusi dati finanziari, risultati dello studio o tempistiche. Le informazioni sono fornite a scopo informativo (non archiviate) e pertanto non sono incorporate per riferimento in altri documenti ai sensi dell鈥橢xchange Act o del Securities Act, salvo diversa indicazione.

Stoke Therapeutics, Inc. (Nasdaq: STOK) present贸 un Formulario 8-K el 10 de julio de 2025 bajo el 铆tem 7.01 (Regulaci贸n FD). El documento indica que la empresa emiti贸 un comunicado de prensa (Exhibici贸n 99.1) anunciando la presentaci贸n de datos de un an谩lisis que inform贸 el dise帽o del estudio de Fase 3 EMPEROR planificado y evalu贸 los posibles efectos del r茅gimen de dosificaci贸n propuesto para zorevunersen. No se incluyeron m茅tricas financieras, resultados del estudio ni cronogramas en el 8-K. La informaci贸n se proporciona (no se presenta) y, por lo tanto, no se incorpora por referencia en otros documentos bajo la Exchange Act o la Securities Act, a menos que se indique espec铆ficamente.

Stoke Therapeutics, Inc. (雮橃姢雼�: STOK)電� 2025雲� 7鞗� 10鞚� 頃 7.01(Regulation FD)鞐� 霐半澕 Form 8-K毳� 鞝滌稖頄堨姷雼堧嫟. 頃措嫻 鞝滌稖 氍胳劀鞐愲姅 須岇偓臧� 瓿勴殟霅� 3靸� EMPEROR 鞐瓣惮 靹り硠鞐� 彀戈碃霅� 攵勳劃 雿办澊韯办檧 鞝滌晥霅� zorevunersen 韴棳 鞖旊矔鞚� 鞛犾灛鞝� 鞓來枼鞚� 韽夑皜頃� 雮挫毄鞚� 氚滍憸頃� 氤措弰鞛愲(歃濍箼鞛愲 99.1)毳� 氚滍憸頄堧嫟瓿� 氇呾嫓霅橃柎 鞛堨姷雼堧嫟. 8-K鞐愲姅 鞛 歆�響�, 鞐瓣惮 瓴瓣臣, 鞚检爼鞚� 韽暔霅橃 鞎婌晿鞀惦媹雼�. 鞚� 鞝曤炒電� 鞝滉车霅� 瓴冹澊氅�(鞝滌稖霅� 瓴冹澊 鞎勲嫎) 霐半澕靹� 氇呾嫓鞝侅溂搿� 鞏戈笁霅橃 鞎婋姅 頃� 雼るジ Exchange Act 霕愲姅 Securities Act 氍胳劀鞐� 彀胳“搿� 韽暔霅橃 鞎婌姷雼堧嫟.

Stoke Therapeutics, Inc. (Nasdaq : STOK) a d茅pos茅 un formulaire 8-K le 10 juillet 2025 en vertu de l鈥檃rticle 7.01 (R猫glement FD). Le d茅p么t indique que la soci茅t茅 a publi茅 un communiqu茅 de presse (Exhibit 99.1) annon莽ant la pr茅sentation de donn茅es issues d鈥檜ne analyse ayant guid茅 la conception de l鈥櫭﹖ude de phase 3 EMPEROR pr茅vue et 茅valu茅 les effets potentiels du sch茅ma posologique propos茅 pour le zorevunersen. Aucun indicateur financier, r茅sultat d鈥櫭﹖ude ou calendrier n鈥檃 茅t茅 inclus dans le 8-K. Les informations sont fournies (non d茅pos茅es) et ne sont donc pas incorpor茅es par renvoi dans d鈥檃utres d茅p么ts au titre de l鈥橢xchange Act ou du Securities Act, sauf indication contraire explicite.

Stoke Therapeutics, Inc. (Nasdaq: STOK) reichte am 10. Juli 2025 ein Formular 8-K unter Punkt 7.01 (Regulation FD) ein. In der Einreichung hei脽t es, dass das Unternehmen eine Pressemitteilung (Anlage 99.1) ver枚ffentlicht hat, in der die Pr盲sentation von Daten aus einer Analyse angek眉ndigt wird, die das Design der geplanten Phase-3-EMPEROR-Studie informierte und die potenziellen Auswirkungen des vorgeschlagenen Dosierungsschemas f眉r Zorevunersen bewertete. Finanzkennzahlen, Studienergebnisse oder Zeitpl盲ne wurden im 8-K nicht enthalten. Die Informationen werden bereitgestellt (nicht eingereicht) und sind daher nicht durch Verweis in andere Exchange Act- oder Securities Act-Einreichungen aufgenommen, sofern nicht ausdr眉cklich angegeben.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine Reg FD update; provides visibility on Phase 3 planning but lacks efficacy or financial data.

The 8-K simply notifies investors that Stoke has released supportive data used to shape its upcoming Phase 3 EMPEROR trial of zorevunersen. Because the document omits the data itself, it offers limited incremental insight into clinical risk or valuation. The disclosure is furnished under Item 7.01, signalling that management views it as informational rather than materially transformative. Absent study results or new guidance, I classify the immediate market impact as neutral.

Stoke Therapeutics, Inc. (Nasdaq: STOK) ha presentato un modulo 8-K il 10 luglio 2025 ai sensi della voce 7.01 (Regolamento FD). Nel documento si comunica che la societ脿 ha rilasciato un comunicato stampa (Allegato 99.1) in cui annuncia la presentazione di dati provenienti da un鈥檃nalisi che ha guidato la progettazione dello studio di Fase 3 EMPEROR previsto e ha valutato i potenziali effetti del regime di dosaggio proposto per zorevunersen. Nel modulo 8-K non sono stati inclusi dati finanziari, risultati dello studio o tempistiche. Le informazioni sono fornite a scopo informativo (non archiviate) e pertanto non sono incorporate per riferimento in altri documenti ai sensi dell鈥橢xchange Act o del Securities Act, salvo diversa indicazione.

Stoke Therapeutics, Inc. (Nasdaq: STOK) present贸 un Formulario 8-K el 10 de julio de 2025 bajo el 铆tem 7.01 (Regulaci贸n FD). El documento indica que la empresa emiti贸 un comunicado de prensa (Exhibici贸n 99.1) anunciando la presentaci贸n de datos de un an谩lisis que inform贸 el dise帽o del estudio de Fase 3 EMPEROR planificado y evalu贸 los posibles efectos del r茅gimen de dosificaci贸n propuesto para zorevunersen. No se incluyeron m茅tricas financieras, resultados del estudio ni cronogramas en el 8-K. La informaci贸n se proporciona (no se presenta) y, por lo tanto, no se incorpora por referencia en otros documentos bajo la Exchange Act o la Securities Act, a menos que se indique espec铆ficamente.

Stoke Therapeutics, Inc. (雮橃姢雼�: STOK)電� 2025雲� 7鞗� 10鞚� 頃 7.01(Regulation FD)鞐� 霐半澕 Form 8-K毳� 鞝滌稖頄堨姷雼堧嫟. 頃措嫻 鞝滌稖 氍胳劀鞐愲姅 須岇偓臧� 瓿勴殟霅� 3靸� EMPEROR 鞐瓣惮 靹り硠鞐� 彀戈碃霅� 攵勳劃 雿办澊韯办檧 鞝滌晥霅� zorevunersen 韴棳 鞖旊矔鞚� 鞛犾灛鞝� 鞓來枼鞚� 韽夑皜頃� 雮挫毄鞚� 氚滍憸頃� 氤措弰鞛愲(歃濍箼鞛愲 99.1)毳� 氚滍憸頄堧嫟瓿� 氇呾嫓霅橃柎 鞛堨姷雼堧嫟. 8-K鞐愲姅 鞛 歆�響�, 鞐瓣惮 瓴瓣臣, 鞚检爼鞚� 韽暔霅橃 鞎婌晿鞀惦媹雼�. 鞚� 鞝曤炒電� 鞝滉车霅� 瓴冹澊氅�(鞝滌稖霅� 瓴冹澊 鞎勲嫎) 霐半澕靹� 氇呾嫓鞝侅溂搿� 鞏戈笁霅橃 鞎婋姅 頃� 雼るジ Exchange Act 霕愲姅 Securities Act 氍胳劀鞐� 彀胳“搿� 韽暔霅橃 鞎婌姷雼堧嫟.

Stoke Therapeutics, Inc. (Nasdaq : STOK) a d茅pos茅 un formulaire 8-K le 10 juillet 2025 en vertu de l鈥檃rticle 7.01 (R猫glement FD). Le d茅p么t indique que la soci茅t茅 a publi茅 un communiqu茅 de presse (Exhibit 99.1) annon莽ant la pr茅sentation de donn茅es issues d鈥檜ne analyse ayant guid茅 la conception de l鈥櫭﹖ude de phase 3 EMPEROR pr茅vue et 茅valu茅 les effets potentiels du sch茅ma posologique propos茅 pour le zorevunersen. Aucun indicateur financier, r茅sultat d鈥櫭﹖ude ou calendrier n鈥檃 茅t茅 inclus dans le 8-K. Les informations sont fournies (non d茅pos茅es) et ne sont donc pas incorpor茅es par renvoi dans d鈥檃utres d茅p么ts au titre de l鈥橢xchange Act ou du Securities Act, sauf indication contraire explicite.

Stoke Therapeutics, Inc. (Nasdaq: STOK) reichte am 10. Juli 2025 ein Formular 8-K unter Punkt 7.01 (Regulation FD) ein. In der Einreichung hei脽t es, dass das Unternehmen eine Pressemitteilung (Anlage 99.1) ver枚ffentlicht hat, in der die Pr盲sentation von Daten aus einer Analyse angek眉ndigt wird, die das Design der geplanten Phase-3-EMPEROR-Studie informierte und die potenziellen Auswirkungen des vorgeschlagenen Dosierungsschemas f眉r Zorevunersen bewertete. Finanzkennzahlen, Studienergebnisse oder Zeitpl盲ne wurden im 8-K nicht enthalten. Die Informationen werden bereitgestellt (nicht eingereicht) und sind daher nicht durch Verweis in andere Exchange Act- oder Securities Act-Einreichungen aufgenommen, sofern nicht ausdr眉cklich angegeben.

FORM 6 – K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report on Foreign Issuer

Pursuant to Rule 13a – 16 or 15d – 16
of the Securities Exchange Act of 1934

For the Month of July 2025

Gilat Satellite Networks Ltd.
(Translation of Registrant’s Name into English)

Gilat House, 21 Yegia Kapayim Street
Daniv Park, Kiryat Arye, Petah Tikva 4913020, Israel
(Address of Principal Corporate Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  ☒    Form 40-F  ☐

Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐   No  ☒

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):   N/A

Attached hereto is Registrant’s press release dated July 10, 2025, announcing that Notice of Annual General Meeting of Shareholders to be held August 14, 2025.

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

 
Gilat Satellite Networks Ltd.
(Registrant)
 
 
 
 
 
Dated July 10, 2025
By:
/s/ Doron Kerbel
 
 
 
Doron Kerbel
 
 
 
General Counsel & Company Secretary
 

Page 2 of 4

GILAT SATELLITE NETWORKS LTD.

Gilat House
21 Yegia Kapayim St.
Kiryat Arye
Petah Tikva 4913020, Israel
____________________

NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

To be held on August 14, 2025

To our Shareholders:

We cordially invite you to the Annual General Meeting of Shareholders of Gilat Satellite Networks Ltd. (the “Company”) to be held at the offices of the Company at 21 Yegia Kapayim Street, Kiryat Arye, Petah Tikva 4913020, Israel, on August 14, 2025 at 12:00 p.m. Israel time for the following purposes (the “Meeting”):


 1.
to set the number of directors serving on the Board of Directors at eight;
 

 2.
to re-elect four members of the Board of Directors and elect one new member of the Board of Directors to serve until the Company’s next annual general meeting of shareholders and until their successors have been duly elected and qualified;
 

 3.
subject to her election pursuant to Item No. 2, to approve a grant of options to Dana Porter Rubinshtein, as described in the Proxy Statement;
 

 4.
to approve of the election of Hilla Haddad Chmelnik as an external director, as defined in the Israeli Companies Law 5759-1999 (the “ICL”), including the approval of her compensation terms, for a three-year period commencing as of the date of approval;
 

 5.
subject to her election pursuant to Item No. 4, to approve a grant of options to Hilla Haddad Chmelnik, as described in the Proxy Statement;
 

 6.
to amend the Company’s Compensation Policy for Executive Officers and Directors, as described in the Proxy Statement;
 

 7.
subject to the amendment of the Company’s Compensation Policy for Executive Officers and Directors pursuant to Item No. 6, to approve the grant of Performance Stock Units (PSU) to Adi Sfadia, the Company’s Chief Executive Officer, as described in the Proxy Statement; and
 

 8.
to ratify and approve the reappointment and compensation of Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, as our independent registered public accountants for the fiscal year ending December 31, 2025, and for such additional period until the next annual general meeting of shareholders.
 
In addition, our consolidated financial statements for the year ended December 31, 2024, will be received and considered at the Meeting.

Page 3 of 4

              Our Board of Directors recommends that you vote “FOR” all proposals under Items 1 through 8, which are described in the attached Proxy Statement.

Shareholders of record at the close of business on July 16, 2025 (the “Record Date”), are entitled to notice of and to vote at the Meeting and any adjournments thereof. You can vote either by mailing in your proxy or in person by attending the Meeting. Only proxies that are received at the offices of the Company at 21 Yegia Kapayim Street, Kiryat Arye, Petah Tikva 4913020, Israel, no later than 10:00 a.m. Israel time, on August 14, 2025, will be deemed received in a timely fashion and the votes therein recorded. If you attend the Meeting, you can revoke your proxy and vote your shares in person. Detailed proxy voting instructions are provided both in the proxy statement and on the enclosed proxy card. Shareholders who hold shares through members of the Tel Aviv Stock Exchange may also vote electronically via the electronic voting system of the Israel Securities Authority up to six hours before the time fixed for the Meeting.

You should receive instructions about electronic voting from the Tel Aviv Stock Exchange member through which you hold your shares. Shareholders may send the Company position papers no later than August 4, 2025, and the last date for submitting a request to include a proposal in accordance with Section 66(b) of the ICL is July 17, 2025.

According to Israel’s Companies Law Regulations (Confirmation of Ownership of Shares for Voting at the General Meeting), 2000, if a shareholder holds shares through a member of the Tel-Aviv Stock Exchange Ltd. (TASE Member) and the ordinary shares are registered in the name of such TASE Member on the books of our registration company, the shareholder may provide the Company, prior to the meeting, with a certification confirming his ownership of the ordinary shares on the record date. Such certification may be obtained at the TASE Member’s offices or may be sent to the shareholder by mail (subject to payment of the cost of mailing), at the election of the shareholder; provided that the shareholder’s request is submitted with respect to a specific securities account.

Pursuant to the Company’s Articles of Association, the quorum required for the Meeting consists of at least two shareholders present, in person or by proxy, who hold or represent between them at least 25% of the Company’s issued and outstanding share capital.

The approval of each of the proposals requires the affirmative vote of a majority of the ordinary shares present, in person or by proxy, and voting on such proposal (not taking into consideration abstentions).  In addition, in order to approve each of Items Nos. 4, 5, 6 and 7, the shareholders’ approval must either (i) include at least a majority of the ordinary shares voted by shareholders who are not controlling shareholders (within the meaning of the ICL) and who are not shareholders who have a personal interest (within the meaning of the ICL) in the approval of such proposal, not taking into consideration abstentions, or (ii) be obtained such that the total ordinary shares of non-controlling shareholders and non-interested shareholders voted against such proposal do not represent more than two percent of the outstanding ordinary shares.

In accordance with the Israeli Companies Regulations (Reliefs for Companies with Securities Listed on Foreign Stock Exchanges), 5760-2000, a shareholder submitting a vote for each of Items Nos. 4, 5, 6 and 7 is deemed to confirm to the Company that such shareholder does not have a “Personal Interest” in such Item and is not a “Controlling Shareholder” (as such terms are defined under the ICL), unless such shareholder had delivered the Company a notice in writing stating otherwise, no later than 10 a.m., Israel time, on August 14, 2025, to the attention of the Company’s Corporate Secretary, at our registered office in Israel, 21 Yegia Kapayim St., Kiryat Arye, Petah Tikva 4913020, Israel.

Shareholders may also review the proxy statement at our principal executive offices stated above, upon prior notice and during regular working hours (telephone number: +972-925-2016) until the date of the Meeting. Copies of this notice, the proxy statement and the proxy card for the meeting will also be available at the following websites: www.edgar.gov, http://www.tase.co.il/tase/, http://www.magna.isa.gov.il (the distribution sites), and http://www.gilat.com.

 
By Order of the Board of Directors,
Doron Kerbel, General Counsel & Corporate Secretary

July 10, 2025

Page 4 of 4

Source:

FAQ

What did Stoke Therapeutics (STOK) announce in its July 10, 2025 Form 8-K?

The company furnished a press release describing data that influenced the design of its Phase 3 EMPEROR study and zorevunersen dosing regimen.

Does the 8-K include actual results from the Phase 3 EMPEROR study?

No. The filing only notes that data informing the study design were presented; specific results are not included.

Is the information in Exhibit 99.1 considered "filed" with the SEC?

No. The company states that the press release is "furnished" under Item 7.01 and is not deemed "filed" under Section 18 of the Exchange Act.

Were any financial statements or earnings figures provided in this 8-K?

No financial statements, revenue figures, or earnings data were included.

What is the trading symbol and exchange listing for Stoke Therapeutics?

Stoke Therapeutics' common stock trades on the Nasdaq Global Select Market under the symbol STOK.
Stock GILT logo
Gilat Satellite

NASDAQ:GILT

GILT Rankings

#4661 Ranked by Market Cap
N/A Ranked by Dividends

GILT Latest News

Jul 22, 2025
Gilat Awarded Approximately $60 Million to Provide Digital Inclusion Solutions in Peru
Jul 21, 2025
Gilat to Report Second Quarter 2025 Results on Wednesday, August 6th
Jul 16, 2025
Gilat Awarded More Than $7 Million to Provide the U.S. Army With Services in Support of Mission-Critical Communications
Jul 9, 2025
Gilat Awarded Over $22 Million in Orders from Tier One Satellite Operators
Jun 10, 2025
Gilat Secures $27 Million for Gilat鈥檚 Stellar Blu Portfolio

GILT Latest SEC Filings

Jul 22, 2025
[6-K] Gilat Satellite Networks Ltd Current Report (Foreign Issuer)
Jul 21, 2025
[6-K] Gilat Satellite Networks Ltd Current Report (Foreign Issuer)
Jul 17, 2025
[SCHEDULE 13G] Gilat Satellite Networks Ltd SEC Filing
Jul 17, 2025
[6-K] Gilat Satellite Networks Ltd Current Report (Foreign Issuer)
Jul 16, 2025
[6-K] Gilat Satellite Networks Ltd Current Report (Foreign Issuer)

GILT Stock Data

421.13M
57.02M
31.93%
0.98%
Communication Equipment
Technology
Israel
Petah Tikva